ClinicalTrials.gg
CompletedNCT05399498Updated Nov 19, 2026Results posted

Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

A Phase 2 interventional study of Psilocybin in Borderline Personality Disorder and Major Depressive Disorder, sponsored by University of Chicago. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Chicago · Phase 2, Interventional, and Treatment

How we know

Updated Nov 19, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Borderline Personality Disorder with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Borderline Personality Disorder · United States.

Enrollment
64th of 71
10 · median 56
Started
2023
with 5 others
Phase 2
16 of 81
1 open now
Registered
64th of 81
by date
Lead sponsor
4 of 81
University of Chicago

Among the 81 studies in Borderline Personality Disorder with a site in United States, this one is the 64th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2023, is one of 16 in phase 2, and was the 64th registered.

Borderline Personality Disorder

279 studies on the registry are indexed under Borderline Personality Disorder; 70 are open to participants now.

Browse Borderline Personality Disorder studies →

Open to participants now

15 of the 81 studies in Borderline Personality Disorder with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Borderline Personality Disorder studies recruiting now, 18 (37%) set no upper age limit and 30 (61%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Borderline Personality Disorder with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).

Read the detailed description

The primary objective of the proposed study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD). Ten subjects with MDD and BPD will receive a single 25 mg oral dose of psilocybin. The hypothesis to be tested is that psilocybin will result significant reduction in symptoms of both MDD and BPD after 1 week and sustained for 4 weeks compared to baseline (improvement in symptoms will be indicated by lower scores on established outcome measures of MDD and BPD symptoms that have been used in prior studies).

03

Conditions studied

  • Borderline Personality Disorder
  • Major Depressive Disorder

Keywords

  • BPD
  • MDD
  • Psilocybin
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65
  • Diagnosed with current major depressive disorder (MDD)
  • Montgomery-Asberg Depression Rating Scale (MADRS) score of > 20
  • Diagnosed with borderline personality disorder (BPD)
  • Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS) score of > 20
  • Ability to understand and sign the consent form

Exclusion criteria

Exclusion Criteria:

  • Unstable medical illness based on history or abnormalities on baseline physical examination
  • Current pregnancy or lactation, or inadequate in women of
  • Illegal substance use based on urine toxicology screening (except cannabis use)
  • Current or past history of bipolar I disorder, schizophrenia, or schizoaffective disorder
  • Active substance use disorder
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Experimental: Psilocybin

    Single 25 mg capsule oral dose of psilocybin

    Drug: Psilocybin

Interventions

06

What researchers measure

Primary outcomes

  1. Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a 10-item, clinician-administered scale that assesses depression symptoms during the last seven days. Each item is rated on a scale from 0 to 6, with 0 being "normal/not present" and 6 being "extreme." Scores from each item are added together to reach a total score. Higher total scores (ranging from 0-60) indicate higher severity levels of depression, while a score of 0 indicates no depressive symptoms. Change in scores from baseline to Visit 5 will be reported.

    Time frame: Baseline/Visit 1/Week 0 to Visit 5/Week 5

  2. Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS) Total Score

    The BPD-SAS covers a two-week time frame and contains 11 items, each representing a different symptom of BPD. Each item is rated on a five-point anchored rating scale of 0-4, with 0 representing no symptoms and 4 representing extreme symptoms. Total scores are computed by adding up the scores for each item (total scores range from 0-44) with higher scores indicating higher levels of severity of BPD symptoms. Change in the total score from Baseline to Visit 5 will be reported.

    Time frame: Baseline/Visit 1/Week 0 to Visit 5/Week 5

Secondary outcomes

  1. Clinical Global Impression - Improvement Scale (CGI-I)

    A clinician administered, single item scale measuring overall improvement of global severity of psychiatric illness. The scale itself assesses overall disorder improvement since baseline on a scale from 1 to 7 with 1 being "Very much improved" and 7 being "Very much worse." Results are reported as the scores from participants on Visit 5.

    Time frame: Visit 2/Week 1 to Visit 5/Week 5

07

Results

Posted Oct 29, 2026

Participant flow

Participant flow — Overall Study
MilestoneExperimental: Psilocybin
Started9
Completed7
Not completed2
Withdrew: 2 participants did not complete all follow-up visits and were not included in the final analysis2

Outcome measures

PrimaryMontgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is a 10-item, clinician-administered scale that assesses depression symptoms during the last seven days. Each item is rated on a scale from 0 to 6, with 0 being "normal/not present" and 6 being "extreme." Scores from each item are added together to reach a total score. Higher total scores (ranging from 0-60) indicate higher severity levels of depression, while a score of 0 indicates no depressive symptoms. Change in scores from baseline to Visit 5 will be reported.

Time frame:
Baseline/Visit 1/Week 0 to Visit 5/Week 5
Reported as:
Mean · score on a scale
Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
score on a scaleExperimental: Psilocybin
Baseline28.56 ± 4.53
Visit 517.22 ± 10.39
PrimaryBorderline Personality Disorder Symptom Assessment Scale (BPD-SAS) Total Score

The BPD-SAS covers a two-week time frame and contains 11 items, each representing a different symptom of BPD. Each item is rated on a five-point anchored rating scale of 0-4, with 0 representing no symptoms and 4 representing extreme symptoms. Total scores are computed by adding up the scores for each item (total scores range from 0-44) with higher scores indicating higher levels of severity of BPD symptoms. Change in the total score from Baseline to Visit 5 will be reported.

Time frame:
Baseline/Visit 1/Week 0 to Visit 5/Week 5
Reported as:
Mean · score on a scale
Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS) Total Score
score on a scaleExperimental: Psilocybin
Baseline32.67 ± 4.18
Visit 528.11 ± 8.98
SecondaryClinical Global Impression - Improvement Scale (CGI-I)

A clinician administered, single item scale measuring overall improvement of global severity of psychiatric illness. The scale itself assesses overall disorder improvement since baseline on a scale from 1 to 7 with 1 being "Very much improved" and 7 being "Very much worse." Results are reported as the scores from participants on Visit 5.

Time frame:
Visit 2/Week 1 to Visit 5/Week 5
Reported as:
Count of participants · Participants
Clinical Global Impression - Improvement Scale (CGI-I)
ParticipantsExperimental: Psilocybin
Very much improved0
Much improved3
Minimally improved3
No change0
Minimally worse1
Much worse0
Very much worse0

Adverse events

Collected over Adverse event data were collected from enrollment until end of follow-up, up to Visit 5/Week 5.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Psilocybin0/9 (0%)1/9 (11.1%)7/9 (77.8%)
Most frequent serious events
Most frequent serious events
EventExperimental: Psilocybin
Psychiatric Hospitalization After Study Drug AdministrationPsychiatric disorders1/9
Most frequent other events
Most frequent other events
EventExperimental: Psilocybin
NauseaGastrointestinal disorders4/9
Cried/Felt EmotionalPsychiatric disorders3/9
Passive Suicidal Ideation at BaselinePsychiatric disorders3/9
Anxious Before DosePsychiatric disorders2/9
DizzinessNervous system disorders1/9
Fatigue/DrowsinessNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Experimental: Psilocybin
<=18 years0
Between 18 and 65 years9
>=65 years0
Age, Continuous
Age, Continuous(years)Experimental: Psilocybin
Mean31.33 ± 13.45
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Experimental: Psilocybin
Female4
Male3
Other2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental: Psilocybin
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White7
More than one race2
Unknown or Not Reported0
Age of Onset of Borderline Personality Disorder (BPD) Symptoms
Age of Onset of Borderline Personality Disorder (BPD) Symptoms(years)Experimental: Psilocybin
Mean15.88 ± 4.05
Age of Onset of Major Depressive Disorder (MDD) Symptoms
Age of Onset of Major Depressive Disorder (MDD) Symptoms(years)Experimental: Psilocybin
Mean13.25 ± 3.28
History of Illicit Psilocybin Usage
History of Illicit Psilocybin Usage(Participants)Experimental: Psilocybin
Yes4
No5
08

Study locations

1 site
  • University of Chicago
    Chicago, Illinois 60637, United States
09

References and documents

Publications

  • Gunderson J: Borderline Personality Disorder, 2nd ed. Washington, DC, American Psychiatric Press, 2000
  • Nakao K, Gunderson JG, Phillips KA, Tanaka N: Functional impairment in personality disorders. J Pers Disord 1992; 6:24-31
  • Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, Korslund KE, Tutek DA, Reynolds SK, Lindenboim N. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry. 2006 Jul;63(7):757-66. doi: 10.1001/archpsyc.63.7.757. PubMed 16818865 ↗
  • Blum N, St John D, Pfohl B, Stuart S, McCormick B, Allen J, Arndt S, Black DW. Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. Am J Psychiatry. 2008 Apr;165(4):468-78. doi: 10.1176/appi.ajp.2007.07071079. Epub 2008 Feb 15. PubMed 18281407 ↗
  • McMain SF, Guimond T, Streiner DL, Cardish RJ, Links PS. Dialectical behavior therapy compared with general psychiatric management for borderline personality disorder: clinical outcomes and functioning over a 2-year follow-up. Am J Psychiatry. 2012 Jun;169(6):650-61. doi: 10.1176/appi.ajp.2012.11091416. PubMed 22581157 ↗
  • Lieb K, Vollm B, Rucker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010 Jan;196(1):4-12. doi: 10.1192/bjp.bp.108.062984. PubMed 20044651 ↗
  • Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, Buschmann W, Rother N, Fartacek R, Egger C, Anvar J, Rother WK, Loew TH, Kaplan P. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006 May;163(5):833-8. doi: 10.1176/ajp.2006.163.5.833. PubMed 16648324 ↗
  • Schulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q, Tanaka Y, Lin D, Deberdt W, Corya S. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008 Dec;193(6):485-92. doi: 10.1192/bjp.bp.107.037903. PubMed 19043153 ↗
  • Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, Deberdt W, Kryzhanovskaya L, Corya S. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011 Oct;72(10):1353-62. doi: 10.4088/JCP.08m04138yel. PubMed 21535995 ↗
  • Pascual JC, Soler J, Puigdemont D, Perez-Egea R, Tiana T, Alvarez E, Perez V. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 2008 Apr;69(4):603-8. doi: 10.4088/jcp.v69n0412. PubMed 18251623 ↗
  • Zanarini MC, Vujanovic AA, Parachini EA, Boulanger JL, Frankenburg FR, Hennen J. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers Disord. 2003 Jun;17(3):233-42. doi: 10.1521/pedi.17.3.233.22147. PubMed 12839102 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Dec 2025, 25 months.

Results were first posted in Oct 2026, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2022
First posted
Jun 1, 2022
StartActual
Nov 1, 2023
Primary completionActual
Dec 1, 2025
CompletionActual
Dec 1, 2025
Results first posted
Oct 29, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted, then revised
posted Oct 29, 2026 · revised Nov 19, 2026
Enrollment
9→10
Oct 29, 2026
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedDiagnosed with current major depressive disorder (MDD)
  • EditedDiagnosed with borderline personality disorder (BPD)
Oct 29, 2026
Primary outcomes
Revised in 2 updates
What changed on Oct 29, 2026
  • EditedChange in Montgomery-Asberg Depression Rating Scale (MADRS) Total ScoreTime frame: Baseline to Week 5 → Baseline/Visit 1/Week 0 to Visit 5/Week 5
  • EditedChange in Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS) Total ScoreTime frame: Baseline to Week 5 → Baseline/Visit 1/Week 0 to Visit 5/Week 5
What changed on Nov 19, 2026
  • EditedChange in Montgomery-Asberg Depression Rating Scale (MADRS) Total ScoreTime frame: Baseline/Visit 1/Week 0 to Visit 5/Week 5
  • EditedChange in Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS) Total ScoreTime frame: Baseline/Visit 1/Week 0 to Visit 5/Week 5
across 2 updates, Oct 29, 2026 – Nov 19, 2026
Documents
Secondary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedClinical Global Impression - Severity scaleImprovement Scale (CGI-SI)Time frame: Baseline to Week 5 → Visit 2/Week 1 to Visit 5/Week 5
  • RemovedClinical Global Impression - Improvement scale (CGI-I)Time frame: Week 2 to Week 5
Oct 29, 2026
Show all 2 updates
  1. Nov 19, 2026
    Posted results revised
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedChange in Montgomery-Asberg Depression Rating Scale (MADRS) Total ScoreTime frame: Baseline/Visit 1/Week 0 to Visit 5/Week 5
    • EditedChange in Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS) Total ScoreTime frame: Baseline/Visit 1/Week 0 to Visit 5/Week 5
  2. Oct 29, 2026
    Results posted
    Enrollment 9→10
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedDiagnosed with current major depressive disorder (MDD)
    • EditedDiagnosed with borderline personality disorder (BPD)
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedChange in Montgomery-Asberg Depression Rating Scale (MADRS) Total ScoreTime frame: Baseline to Week 5 → Baseline/Visit 1/Week 0 to Visit 5/Week 5
    • EditedChange in Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS) Total ScoreTime frame: Baseline to Week 5 → Baseline/Visit 1/Week 0 to Visit 5/Week 5
    Secondary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedClinical Global Impression - Severity scaleImprovement Scale (CGI-SI)Time frame: Baseline to Week 5 → Visit 2/Week 1 to Visit 5/Week 5
    • RemovedClinical Global Impression - Improvement scale (CGI-I)Time frame: Week 2 to Week 5
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05399498
Collaborators
Usona Institute
Responsible party
Sponsor
First posted
Jun 1, 2022
Start date
Nov 1, 2023
Primary completion
Dec 1, 2025
Completion
Dec 1, 2025
Results posted
Oct 29, 2026
Last update
Nov 19, 2026

Study contacts

Jon E Grant, MD, JD, MPH
principal investigator · University of Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion